跳转至内容
Merck
CN

主要文件

查看所有文档

SML0534

维替泊芬

≥94% (HPLC), powder, YAP-TEA domain interaction inhibitor

别名:

反式-18-乙烯基-4,4a-二氢-3,4-双（甲氧羰基）-4a，8,14,19-四甲基-23H，25H-苯并[b]卟吩-9,13-二丙酸单甲酯, 维速达尔, （4R，4aS）-rel-18-乙烯基-4,4a-二氢-3,4-双（甲氧羰基）-4a，8,14,19-四甲基-24H，26H-苯并[b]卟吩-9,13-二丙酸单甲酯

登录 查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式（希尔记法）:
C41H42N4O8
化学文摘社编号:
129497-78-5
分子量:
718.79
UNSPSC Code:
12352200
PubChem Substance ID:
329825538
NACRES:
NA.77
MDL number:
MFCD11982858
Assay:
≥94% (HPLC)
Form:
powder
Quality level:
100
Storage condition:
desiccated, protect from light
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

维替泊芬, ≥94% (HPLC)

Quality Level

100

assay

≥94% (HPLC)

form

powder

storage condition

desiccated, protect from light

solubility

DMSO: 2 mg/mL, clear (warmed)

storage temp.

−20°C

SMILES string

CC(C(/C=C1[C@@]2(C)C(/C(N/1)=C/3)=CC=C(C(OC)=O)[C@H]2C(OC)=O)=N/4)=C(CCC(OC)=O)C4=C\C5=C(CCC(O)=O)C(C)=C(/C=C6C(C=C)=C(C)C3=N/6)N5.CC(C(/C=C7[C@@]8(C)C(/C(N/7)=C/9)=CC=C(C(OC)=O)[C@H]8C(OC)=O)=N/%10)=C(CCC(O)=O)C%10=C\C%11=C(CCC(OC)=O)C(C)=C(/C=C%12C(C=C)

InChI

1S/2C41H42N4O8/c1-9-23-20(2)29-17-34-27-13-10-26(39(49)52-7)38(40(50)53-8)41(27,5)35(45-34)19-30-22(4)24(11-14-36(46)47)32(44-30)18-33-25(12-15-37(48)51-6)21(3)28(43-33)16-31(23)42-29;1-9-23-20(2)29-17-34-27-13-10-26(39(49)52-7)38(40(50)53-8)41(27,5)35(45-34)19-30-22(4)25(12-15-37(48)51-6)33(44-30)18-32-24(11-14-36(46)47)21(3)28(43-32)16-31(23)42-29/h2*9-10,13,16-19,38,43,45H,1,11-12,14-15H2,2-8H3,(H,46,47)/b31-16-,32-18-,34-17-,35-19-;31-16-,33-18-,34-17-,35-19-/t2*38-,41+/m00/s1

InChI key

YHNBVDZVUQFVLS-SKJZPIBWSA-N

Application

维替泊芬已被用作光敏剂。它还可用作YAP（Yes-相关蛋白）-TEA结构域（TEAD）相互作用的抑制剂。

Biochem/physiol Actions

维替泊芬具有破坏YAP（Yes-相关蛋白）/TAZ（具有PDZ结合基序的转录共激活因子）和TEA结构域（TEAD）复合物之间的相互作用的能力。它还可降低卵巢癌细胞的活力，并几乎消除细胞迁移。因此，维替泊芬被认为是治疗卵巢癌的有效方法。
维替泊芬是一种光动力疗法的光敏剂。
维替泊芬是一种用于光动力疗法的光敏剂，可用于消除与黄斑变性等病症相关的眼内异常血管。维替泊芬可在异常血管中积聚，当在氧气存在下被波长为693nm的非热红光刺激时，可产生高反应性的短寿命单线态氧和其他活性氧自由基，从而导致局部内皮损伤和血管阻塞。维替泊芬主要定位于线粒体中。

Other Notes

光敏感

Still not finding the right product?

Explore all of our products under 维替泊芬

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
066M4744V
066M4721V
035M4758V
124M4724V
104M4741V

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

商品

DISCOVER Bioactive Small Molecules for Nitric Oxide & Cell Stress Research

DISCOVER Bioactive Small Molecules for Nitric Oxide & Cell Stress Research

Alan F Cruess et al.
Acta ophthalmologica, 87(2), 118-132 (2008-06-26)
Photodynamic therapy (PDT) with verteporfin has been used less comprehensively in the treatment of exudative age-related macular degeneration (AMD), and specifically of choroidal neovascularization (CNV), since the advent of antiangiogenic therapies. Recently, there has been a renewed interest in PDT
Kevin Tozer et al.
Ophthalmology, 120(10), 2029-2034 (2013-05-30)
To examine the outcomes of combination anti-vascular endothelial growth factor (VEGF) and photodynamic therapy (PDT) for the treatment of neovascular age-related macular degeneration (AMD) refractory to anti-VEGF monotherapy. Retrospective, interventional case series. Twenty-six eyes of 26 patients treated with anti-VEGF
Wai Man Chan et al.
Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 248(5), 613-626 (2010-02-18)
Verteporfin photodynamic therapy (PDT) is approved for the treatment of predominantly classic subfoveal choroidal neovascularization (CNV) due to age-related macular degeneration (AMD), as well as for subfoveal CNV due to pathologic myopia and ocular histoplasmosis syndrome. Verteporfin PDT addresses the
查看所有相关文献

全球贸易项目编号

货号GTIN
SML0534-5MG04061837084782
SML0534-25MG04061837084775